- Our Doctors
- Dr Xue-Yan Jiang
Dr Xue-Yan Jiang
Clinical Oncologist. BSc, MSc (Biomed), (MBBS)
Languages spoken
English, Chinese (Mandarin)
Expert in
Prostate cancer, bladder cancer, kidney cancers
Overview
Centres
Specialises in
Treatments
Dr Xue-Yan Jiang is a highly experienced Consultant Clinical Oncologist with a specialist focus on urological cancers, including prostate, kidney, and bladder cancers. She is known for her compassionate approach, clinical excellence, and commitment to patient-centred care.
Dr Jiang graduated with Merits in Medicine from Newcastle University in 2008 and also holds a BSc and MSc in Biomedical Sciences from Northumbria University. She was appointed as a Consultant in 2020 at the Northern Centre for Cancer Care (NCCC), Freeman Hospital, part of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
In addition to her clinical work, Dr Jiang plays a key role in clinical governance, with a strong focus on quality improvement and patient safety. Her research interests include radiotherapy innovations, advanced imaging techniques, bone health, and cancer biomarkers, contributing to ongoing advancements in cancer care.
Dr Jiang is also deeply committed to medical education and mentorship. She serves as both a clinical and educational supervisor for resident doctors, pharmacists, and Advanced Clinical Practitioners (ACPs), helping to shape the next generation of oncology professionals.
Whether you're seeking expert care for a urological cancer diagnosis or looking for a second opinion, Dr Jiang offers a thoughtful, evidence-based approach tailored to each individual’s needs.
Expertise and interests
- Bladder Cancer
- Kidney cancer
- Prostate cancer
- Radiotherapy
- Imaging
- Bone health
- Biomarkers
- Education
- Clinical trials
Professional memberships
- Member of Royal College of Physicians (Edinburgh) (MRCP)
- Fellow of Royal College of Radiologist (FRCR) UK
Publications & affiliations
- High-dose palliative radiotherapy in metastatic castrate-resistant prostate cancer – is it worthwhile? A single-centre outcome. (September 2022Clinical Oncology 34:e6)
- High dose palliative radiotherapy in bladder cancer - A single centre experience from the UK. (August 2021Radiotherapy and Oncology 161:S1152-S1153)
- Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. (Clinical Oncology 32 (2020) e177ee187)
- Prostate Ultra hypnofraction – Rising to Challenges Presents Opportunities in the COVID-19 Era. (Clinical Oncology 33 (2021) e90)
- Optimising bone health management in advanced prostate cancer: A comparative cohort study. (February 2023 Journal of Clinical Oncology 41(6_suppl):133-133)